OBJECTIVE. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is extensively expressed by advanced atherosclerotic lesions and may play a role in plaque instability. We selected a group of elderly subjects that underwent transcatheter aortic valve implantation (TAVI) or balloon angioplasty (BA) and separated them into two groups, diabetic and nondiabetic, to compare the level of Lp-PLA₂ mass between them. METHODS. 44 patients aged 79.6 ± 5.6 years with symptomatic severe aortic valve stenosis underwent TAVI (n = 35) or BA (n = 9). 21 subjects had confirmed type 2 diabetes mellitus. Lp-PLA₂ mass was measured using an enzyme-linked immunosorbent assay kit (USCN Life Science, China) before and 3 days after the procedure. RESULTS. Lp-PLA₂ mass was significantly elevated in this population (1296 ± 358 ng/mL before TAVI; 1413 ± 268 ng/mL before BA) and further increased after TAVI (1604 ± 437 ng/mL, P < 0.01) or BA (1808 ± 303 ng/mL, P < 0.01). Lp-PLA₂ mass was significantly increased on the diabetic group before these interventions. CONCLUSION. Lp-PLA₂ may be a novel biomarker for the presence of rupture-prone atherosclerotic lesions in elderly patients. Levels of Lp-PLA₂ in diabetic patients may accompany the higher amount of small dense LDL particles seen in these subjects.

1st Department of Internal Medicine Cardioangiology University Hospital Hradec Králové Medical Faculty Charles University 50005 Hradec Králové Czech Republic

3rd Department of Internal Medicine Metabolism and Gerontology University Hospital Hradec Králové Medical Faculty Charles University 50005 Hradec Králové Czech Republic

Department of Cardiosurgery University Hospital Hradec Králové Medical Faculty Charles University 50005 Hradec Králové Czech Republic

Department of Immunology and Alergology University Hospital Hradec Králové Medical Faculty Charles University 50005 Hradec Králové Czech Republic

Zobrazit více v PubMed

Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010;122(21):2183–2200. PubMed

Hui DY. Phospholipase A2 enzymes in metabolic and cardiovascular diseases. Current Opinion in Lipidology. 2012;23(3):235–240. PubMed PMC

Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Current Opinion in Lipidology. 2003;14(4):347–352. PubMed

Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2) Cardiovascular Drugs and Therapy. 2009;23(1):73–83. PubMed

Macphee CH, Nelson JJ, Zalewski A. Lipoprotein-associated phospholipase A2 as a target of therapy. Current Opinion in Lipidology. 2005;16(4):442–446. PubMed

Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(5):923–931. PubMed

Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clinical Chemistry. 2005;51(12):2264–2273. PubMed

Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787–790. PubMed

Kohno M, Yokokawa K, Yasunari K, et al. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation. 1998;98(4):353–359. PubMed

Parenica J, Nemec P, Tomandl J, et al. Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated with transcatheter or surgical aortic valve implantation. PLoS ONE. 2012;7(12)e48851 PubMed PMC

Rosenson RS. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Current Opinion in Lipidology. 2010;21(6):473–480. PubMed

Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. The EPMA Journal. 2011;2(1):27–38. PubMed PMC

Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A2 and atherosclerosis. Current Opinion in Lipidology. 2009;20(5):415–420. PubMed

Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. The American Journal of Cardiology. 2008;101(12A):34F–40F. PubMed

Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Jr., Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(1):216–221. PubMed

Dohi T, Miyauchi K, Okazaki S, et al. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis. 2011;219(2):907–912. PubMed

Epps KC, Wilensky RL. Lp-PLA2 a novel risk factor for high-risk coronary and carotid artery disease. Journal of Internal Medicine. 2011;269(1):94–106. PubMed

Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis Supplements. 2002;3(4):57–68. PubMed

Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837–842. PubMed

Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. Journal of Diabetes and Its Complications. 2006;20(6):343–348. PubMed

Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Glycoprotein Ibα polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients. Diabetes. 2007;56(5):1429–1435. PubMed

Sonoki K, Iwase M, Sasaki N, et al. Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 2009;86(2):117–123. PubMed

Iwase M, Sonoki K, Sasaki N, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis. 2008;196(2):931–936. PubMed

Sánchez-Quesada JL, Vinagre I, Juan-Franco ED, et al. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. The American Journal of Cardiology. 2012;110(1):67–71. PubMed

Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellituss. Cardiovascular Diabetology. 2012;11, article 109 PubMed PMC

Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24(2):e13–e18. PubMed